Zymeworks to Showcase Innovations at Upcoming Investor Events
Zymeworks Announces Participation in Investor Conferences
VANCOUVER, British Columbia -- Zymeworks Inc. (Nasdaq: ZYME), a pioneering clinical-stage biotechnology firm, is excited to reveal its participation in several important investor conferences. The company is devoted to developing innovative biotherapeutics aimed at addressing tough diseases, including various forms of cancer, inflammation, and autoimmune disorders.
Upcoming Conference Schedule
Management at Zymeworks is gearing up for two significant events:
Needham 24th Annual Virtual Healthcare Conference
The team will engage in virtual one-on-one meetings and present insights on April 8, with the presentation scheduled for 9:30 am Eastern Time (ET).
Stifel 2025 Virtual Targeted Oncology Forum
On April 9 at 12:30 pm ET, Zymeworks’ leadership will take part in virtual one-on-one meetings and a fireside chat, discussing the latest developments and strategies in biotechnology.
About Zymeworks Inc.
Zymeworks is leading the way in biotechnology, focusing on the research, development, and commercialization of groundbreaking, multifunctional biotherapeutics. The company is on a mission to make significant contributions to the lives of individuals affected by challenging conditions like cancer and other serious diseases.
Utilizing its proprietary Azymetric™ technology, Zymeworks has developed zanidatamab, a HER2-targeted bispecific antibody. This innovative treatment has garnered attention for its potential to address a range of cancers effectively.
Recent Achievements and Pipeline Progress
Recently, the U.S. FDA granted accelerated approval for Ziihera (zanidatamab-hrii) 50mg/mL for intravenous administration. This treatment is now recognized as the first and only dual HER2-targeted bispecific antibody approved for patients with previously-treated, unresectable, or metastatic HER2-positive biliary tract cancer (BTC) in the U.S. Furthermore, zanidatamab is currently undergoing regulatory evaluation in the EU and China.
Zymeworks continues to expand its portfolio with a robust pipeline of product candidates. The company’s ongoing projects include ZW171 and ZW191, which are in active Phase 1 studies. Additionally, they are preparing to file an investigational new drug application for ZW251, expected in the near future.
Strategic Partnerships
The company has solidified its growth through collaborations with renowned biopharmaceutical firms, enhancing its research and development capabilities. Through these strategic partnerships, Zymeworks aims to advance its therapeutic platforms and further leverage its innovations.
To stay informed about Zymeworks’ progress and updates, visit their official website at www.zymeworks.com or follow them on X at @ZymeworksInc.
Contact Information
Investor Inquiries:
Shrinal Inamdar
Senior Director, Investor Relations
(604) 678-1388
ir@zymeworks.com
Media Inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
media@zymeworks.com
Frequently Asked Questions
What does Zymeworks focus on?
Zymeworks specializes in the discovery and development of innovative biotherapeutics to treat complex diseases.
What conferences will Zymeworks participate in?
Zymeworks will participate in the Needham Annual Virtual Healthcare Conference and the Stifel Virtual Targeted Oncology Forum.
What significant product has Zymeworks developed?
Zymeworks developed zanidatamab, a bispecific antibody targeting HER2.
What recent approvals has Zymeworks received?
Zymeworks received accelerated approval from the U.S. FDA for Ziihera to treat HER2-positive biliary tract cancer.
How can I learn more about Zymeworks?
Visit their website at www.zymeworks.com for more information and updates.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
